What is BIIB's current stock price?

As of now, BIIB is trading at $168.57, with a daily change of -0.44%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

BIIB Stock Analysis & IQ Rating | Biogen

BIIB

Biogen

$168.57

-$0.74 | -0.44%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$190.2

MKT CAP

$24.73B

52W Low

$110.04

VOL

$1.54M

P/E Ratio

15.37

AVG VOL

$2.14M

RSI

39.56

TREND

Sideways

BIIB Stock IQ

Login to see Biogen (BIIB) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

BIIB Target Price

Login to display

Strengths

BIIB Rewards

Trading below its fair value

BIIB Rewards

Outperform the market

BIIB Price Performance

$172.03 (-2.01%)

$146.69 (+14.92%)

$139.31 (+21.00%)

$143.93 (+17.12%)

1year

6month

3month

1month

BIIB Risk Level

BIIB has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

BIIB Analysts Opinion

BIIB overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

BIIB Analysts Opinion

BIIB Analysts opinion is negative and it remained unchanged from the past 3 months

BIIB Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

88%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

50%

33%

86%

BIIB Street Sentiment

BIIB Street Sentiment is extremely bullish and have negative views on the near-term outlook

BIIB Performance Sentiment

Sentiments overview associated with BIIB events and the stock performance.

88%

13%

Positive

Negative

7 out of 8
events present

1 out of 8
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$169.31

Resistance
Price

$169.20

Current Price Range

$187.62

Show methods +

Linked to BIIB

IQ

Close Price

Change

AMGN

4.00

330.03

+0.32%

CHRS

2.05

1.66

+3.75%

BNTX

2.75

106.07

-2.80%

ALVO

2.25

4.95

-1.00%

Recently Viewed

Close Price

Change

BIIB

Biogen

168.57

-0.44%

HPQ

HP

20.61

-0.77%

KPLT

Katapult Holdings In

6.92

-0.29%

WLYB

John Wiley &

32.95

+0.33%

NEO

NeoGenomics Com

12.83

-2.95%

BIIB Latest Analysis +

Biogen Sees $1.26 Per Share Impact From IPR&D Milestone Expenses In Q4 . (RTTNews) - Biogen Inc. (BIIB) expects its fourth-quarter 2025 results to include approximately $222 million in acquired in-process research and development (IPR&D) upfront and milestone expenses on a pre-tax basis the company said in an SEC filing. The charge is expected to r

Wed Jan 14, 2026

$169.31 | -5.04%

Activity

Biogens Q4 preliminary EPS comes in below consensus.

Wed Jan 14, 2026

$169.31 | -5.04%

Earnings

Biogen Receives European Nod For High-Dose Regimen Of SPINRAZA In Spinal Muscular Atrophy . (RTTNews) - Biogen Inc. (BIIB) announced that the European Commission has granted marketing authorisation for a high-dose regimen of SPINRAZA comprised of 50 mg/5 mL and 28 mg/5 mL doses for 5q spinal muscular atrophy.

Tue Jan 13, 2026

$178.30 | -3.95%

Activity

Biogen Gains EU Approval For High-Dose SPINRAZA Regimen In SMA . (RTTNews) - Biogen Inc. (BIIB) announced that the European Commission has granted marketing authorization for a high dose regimen of SPINRAZA (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA).

Tue Jan 13, 2026

$178.30 | -3.95%

Activity

Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.

Mon Jan 12, 2026

$185.63 | -1.06%

Activity

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy. CAMBRIDGE Mass. Jan. 12 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) today announced the European Commission (EC) has granted marketing authorization for a high dose regimen of SPINRAZA® (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA). 5q SMA is the most common form of the disease and represents approximatel

Mon Jan 12, 2026

$185.63 | -1.06%

Activity

Proximity Health Solutions and Biogen Named Finalists for the SCOPE 26 Participant Engagement Award. STAMFORD Conn. Jan. 8 2026 /PRNewswire/ -- Proximity Health Solutions in collaboration with Biogen announces that Better Together: Sharing Our Lupus Stories has been selected as one of the four finalists for the prestigious 2026 SCOPE Participant Engagement Award. The Better Together...

Thu Jan 8, 2026

$186.00 | -0.49%

Activity

FAQ About BIIB Stock Insights

What is BIIB current stock price?

What are BIIB stock strengths?

What is BIIB Risk Level?

What is BIIB market cap and volume?

What is BIIB current Stock IQ?

Should I buy BIIB stock right now?

Is BIIB a Strong Buy right now?

What does a 'Strong Buy' rating mean for BIIB?

What does a 'Strong Sell' rating mean for BIIB?

What factors influence BIIB's Stock IQ?

Explore our BIIB Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored BIIB Stock Strategies
Effective Risk Management

FIND US ON

Receive our BIIB Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

BIIB

Biogen

Set Alerts

Current Price

$168.57

-$0.74 | -0.44%

52W High

$190.2

MKT CAP

$24.73B

52W Low

$110.04

VOL

$1.54M

P/E Ratio

15.37

AVG VOL

$2.14M

RSI

39.56

TREND

Sideways

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

BIIB Stock IQ

Login to unlock Biogen (BIIB) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

BIIB Rewards

Trading below its fair value

BIIB Rewards

Outperform the market

Linked to BIIB

Symbol

IQ

Close

Change

AMGN

4.00

330.03

+0.32%

CHRS

2.05

1.66

+3.75%

BNTX

2.75

106.07

-2.80%

ALVO

2.25

4.95

-1.00%

BIIB Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

88%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

50%

33%

86%

BIIB Street Sentiment

BIIB Street Sentiment is extremely bullish and have negative views on the near-term outlook

BIIB Risk Level

BIIB has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

BIIB Performance Sentiment

Sentiments overview associated with BIIB events and the stock performance.

88%

13%

Positive

Negative

7 out of 8
events present

1 out of 8
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$169.31

Resistance
Price

$169.20

Current Price Range

$187.62

Show methods +

BIIB Latest Analysis

Biogen Sees $1.26 Per Share Impact From IPR&D Milestone Expenses In Q4 . (RTTNews) - Biogen Inc. (BIIB) expects its fourth-quarter 2025 results to include approximately $222 million in acquired in-process research and development (IPR&D) upfront and milestone expenses on a pre-tax basis the company said in an SEC filing. The charge is expected to r

Wed Jan 14, 2026

$169.31 | -5.04%

Activity

Biogens Q4 preliminary EPS comes in below consensus.

Wed Jan 14, 2026

$169.31 | -5.04%

Earnings

Biogen Receives European Nod For High-Dose Regimen Of SPINRAZA In Spinal Muscular Atrophy . (RTTNews) - Biogen Inc. (BIIB) announced that the European Commission has granted marketing authorisation for a high-dose regimen of SPINRAZA comprised of 50 mg/5 mL and 28 mg/5 mL doses for 5q spinal muscular atrophy.

Tue Jan 13, 2026

$178.30 | -3.95%

Activity

Biogen Gains EU Approval For High-Dose SPINRAZA Regimen In SMA . (RTTNews) - Biogen Inc. (BIIB) announced that the European Commission has granted marketing authorization for a high dose regimen of SPINRAZA (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA).

Tue Jan 13, 2026

$178.30 | -3.95%

Activity

Biogen Inc. (BIIB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.

Mon Jan 12, 2026

$185.63 | -1.06%

Activity

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy. CAMBRIDGE Mass. Jan. 12 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) today announced the European Commission (EC) has granted marketing authorization for a high dose regimen of SPINRAZA® (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA). 5q SMA is the most common form of the disease and represents approximatel

Mon Jan 12, 2026

$185.63 | -1.06%

Activity

Proximity Health Solutions and Biogen Named Finalists for the SCOPE 26 Participant Engagement Award. STAMFORD Conn. Jan. 8 2026 /PRNewswire/ -- Proximity Health Solutions in collaboration with Biogen announces that Better Together: Sharing Our Lupus Stories has been selected as one of the four finalists for the prestigious 2026 SCOPE Participant Engagement Award. The Better Together...

Thu Jan 8, 2026

$186.00 | -0.49%

Activity

Discover BIIB Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of BIIB. We're here to help you make informed investment decisions today.

FIND US ON

Receive our BIIB Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

BIIB Stock trends

BIIB Stock performance

BIIB Stock analysis

BIIB investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing BIIB

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing BIIB

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

BIIB Stock Analysis & IQ Rating | Biogen

BIIB Stock IQ

BIIB Target Price

BIIB Risk Level

BIIB Analysts Opinion

BIIB Street Sentiment

BIIB Performance Sentiment

Technical Price Levels

Explore our BIIB Stock insights

Receive our BIIB Daily Alerts

BIIB Street Sentiment

BIIB Risk Level

Technical Price Levels

Discover BIIB Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of BIIB. We're here to help you make informed investment decisions today.

Receive our BIIB Daily Alerts

BIIB Alerts